Affimed (NASDAQ:AFMD – Get Rating) – Investment analysts at Cantor Fitzgerald issued their FY2022 EPS estimates for Affimed in a research report issued on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the biopharmaceutical company will post earnings of ($0.63) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Affimed’s current full-year earnings is ($0.68) per share. Cantor Fitzgerald also issued estimates for Affimed’s FY2023 earnings at ($0.88) EPS.
Affimed (NASDAQ:AFMD – Get Rating) last posted its quarterly earnings data on Thursday, August 11th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $7.78 million for the quarter, compared to analyst estimates of $8.12 million. Affimed had a negative net margin of 232.11% and a negative return on equity of 54.94%.
Affimed Trading Up 0.5 %
NASDAQ AFMD opened at $2.03 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.89 and a current ratio of 4.90. The firm has a market cap of $250.54 million, a PE ratio of -2.94 and a beta of 2.32. Affimed has a one year low of $1.93 and a one year high of $7.35. The firm’s fifty day moving average is $2.83 and its two-hundred day moving average is $3.30.
Institutional Trading of Affimed
A number of institutional investors have recently added to or reduced their stakes in the stock. Verition Fund Management LLC purchased a new stake in Affimed during the second quarter worth about $98,000. Walleye Capital LLC purchased a new stake in Affimed during the second quarter worth about $1,092,000. Woodline Partners LP purchased a new stake in Affimed during the second quarter worth about $6,953,000. Price T Rowe Associates Inc. MD boosted its holdings in Affimed by 30.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 3,202 shares in the last quarter. Finally, DAFNA Capital Management LLC boosted its holdings in Affimed by 20.1% during the second quarter. DAFNA Capital Management LLC now owns 686,282 shares of the biopharmaceutical company’s stock worth $1,901,000 after buying an additional 115,000 shares in the last quarter. Hedge funds and other institutional investors own 71.08% of the company’s stock.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.
- Get a free copy of the StockNews.com research report on Affimed (AFMD)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.